The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

III.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

Publications

Hekmat H, Vahabi Z, Shojaeifard M, Mirzadeh FS

Diffuse alveolar hemorrhage; An under-diagnosed and rare complication of glycoprotein IIb/IIIa inhibitors.

Journal of cardiovascular and thoracic research. 2022;14(3):201-204

Mikkilineni H, Bruhl SR, Colyer WR, Pandya U

A retrospective analysis and case series of glycoprotein IIb/IIIa inhibitor associated diffuse alveolar hemorrhage: two case reports.

Cases journal. 2009;2:8553

Parakh S, Naik N, Rohatgi N, Bhat U, Parakh K

Eptifibatide overdose.

International journal of cardiology. 2009;131(3):430-2

Iskandar SB, Kasasbeh ES, Mechleb BK, Garcia I, Jackson A, Fahrig S, Albalbissi K, Henry PD

Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors.

Journal of interventional cardiology. 2006;19(4):356-63

Orford JL, Fasseas P, Holmes DR, Berger PB

Alveolar hemorrhage associated with periprocedural eptifibatide administration.

The Journal of invasive cardiology. 2004;16(6):341-2